AZD 3427 (NCT04630067)

Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427
A Phase Ia/b Randomized, Single-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of Single Ascending Doses of AZD3427 in Healthy Volunteers and Multiple Ascending Doses of AZD3427 in Patients With Heart Failure (HFrEF and HF With EF ≥ 41%).

PI: Emerson Perin, MD, PhD
Sponsor: AstraZeneca

ACTIVE ENROLLING  SIGN UP

 
AZ-Advarra-Patient-Brochure